A Prospective, Multicentric Study, To Evaluate The Effectiveness And Safety Of Milk Of Magnesia+Liquid Paraffin+Sodium Picosulfate In The Treatment Of Constipation Symptoms In Post Ano-Rectal Surgical Patients - NA

Start Date29 Jul 2024

Sponsor / Collaborator

Abbott India Ltd.

TCTR20230816005

Phase 2/3IIT

The effects of milk of magnesia for prevention post-operative ileus after hysterectomy: A randomized controlled trial

Start Date25 Sep 2023

Sponsor / Collaborator-

NCT05216328

/ RecruitingPhase 4IIT

OMAMA-study - Prevention of Opioid-induced Constipation in Patients With Advanced Cancer

More than 70% of patients with cancer in the palliative phase have pain that often requires treatment with opioids (morphine-like agents). Constipation occurs in 59% of patients treated with opioids. Opioid-induced constipation (OIC) has consequences that range from daily discomfort with social insecurity and disability to intestinal obstruction. It leads to limitations in self-management, a reduced quality of life and a risk of the need for more care. In the guideline "Diagnosis and treatment of pain in patients with cancer" it is recommended to start preventively with an osmotic laxative such as macrogol/electrolytes or magnesium hydroxide when starting opioids. Macrogol/electrolytes has been proven to be effective for OIC, but is sometimes perceived by patients as unpleasant due to its taste. Magnesium hydroxide, which is less commonly prescribed for OIC, has a neutral taste. Although it is mentioned in the guideline, it is not studied for the treatment of OIC and also not officially registered for this. To support the advice of the guideline and to prove that a choice is possible, it is important to investigate whether there are differences in effectiveness and/or side effects between macrogol/electrolytes and magnesium hydroxide in the prevention of OIC.
The aim of this study is to compare macrogol/electrolytes with magnesium hydroxide in the prevention of opioid-induced constipation in patients with cancer in the palliative (incurable) phase, who start opioids because of pain. The choice of laxative is determined by drawing lots (randomisation). After two weeks, its effect will be assessed and will be presented as the percentage of patients who have not developed constipation after starting opioids. If the laxative, as assigned by lot, is described as satisfactory by the patient, the patient can continue with the drug that the patient used, after the study through regular prescription.
The investigators will ask the patients in the study about their satisfaction with the laxative used, any side effects and the degree of pain. Furthermore, the appeal to care for possible constipation will be examined. Because the best attainable quality of life in the palliative phase is the objective of all care, the investigators will also measure this perceived quality with a questionnaire in this study. The results of this study will lead to the best achievable prevention of opioid constipation in patients with cancer in the palliative phase.

Start Date02 Dec 2022

Sponsor / Collaborator

Stichting Onderzoek Cancer Center Amsterdam

[+12]

100 Clinical Results associated with Magnesium Hydroxide

100 Translational Medicine associated with Magnesium Hydroxide

100 Patents (Medical) associated with Magnesium Hydroxide

15,629

Literatures (Medical) associated with Magnesium Hydroxide

31 Dec 2025·Science and Technology of Advanced Materials

Removal of HCl from a gas phase by MgO under atmospheric conditions

Article

Author: Matsuhashi, Hiromi ; Takahashi, Kazuya ; Kondo, Takahiro ; Kidera, Masanori ; Kitagawa, Michiko

Ensuring the safety of researchers by protecting them from exposure to toxic gases in laboratories is of paramount importance. This study investigated the effectiveness of using high-surface-area MgO to remove HCl under atmospheric conditions. Two types of MgO were synthesized through the thermal decomposition 1-1-1, Tennodai, Tsukuba, of Mg(OH)₂ and MgC₂O₄·2 H₂O. HCl diluted with air passed through both MgO samples, and the amounts of HCl removed and morphological changes in the samples were compared. No significant differences in surface area or crystallinity were observed with the decomposition temperatures. X-ray diffraction analysis showed that the sample prepared from MgC₂O₄·2 H₂O reacted with HCl immediately upon introducing HCl gas. In contrast, the sample obtained from Mg(OH)₂ exhibited only MgO peaks, even 30 min after the introduction of HCl gas. Microscopic analysis revealed that the samples derived from Mg(OH)₂ showed no significant changes in shape after the reaction, whereas the MgO prepared from MgC₂O₄·2 H₂O exhibited substantial changes in overall shape. No correlation was observed between the surface area and the amount of HCl removed. When MgO is prepared from MgC₂O₄·2 H₂O, the reaction occurs in the bulk material, whereas when MgO is prepared from Mg(OH)₂, the reaction hardly progresses after HCl adsorbs onto the MgO surface. The order of magnitude of HCl removal was consistent with the base catalytic activity of the decomposition of diacetone alcohol to acetone. These results suggest that, compared with MgO obtained from Mg(OH)₂, MgO derived from MgC₂O₄·2 H₂O generates more active sites, resulting in the reaction with HCl from surface to progress into bulk.

01 Aug 2025·Journal of Materials Science & Technology

Exploiting supported vanadium catalyst for single-walled carbon nanotube synthesis

Author: Ding, Feng ; He, Maoshuai ; Bi, Jifu ; Han, Fangqian ; An, Hao ; Wu, Qianru

Single-walled carbon nanotubes (SWNTs) with enriched (n, m) species are in high demand for various advanced applications.Since the SWNT structure is largely influenced by the chem. of the active catalyst during growth process, exploiting novel catalyst with bias towards specific SWNT chiralities has been challenging.In this work, we introduce a vanadium catalyst supported by mesoporous magnesia (V-MgO) for the selective growth of SWNTs using CO chem. vapor deposition (CVD).At a reaction temperature of 650°C, the (6, 5) SWNT content reaches an impressive 67.9% among all semiconducting species, exceeding the selectivity of many com. SWNT products.Post-CVD anal. reveals that the catalyst transforms into vanadium carbide (VC), which acts as a nucleation site for SWNT growth.Mol. dynamics simulations indicate that the energy at the SWNT-VC interface and the growth kinetics of SWNTs contribute to the chirality selectivity.This research opens up possibilities for the selective synthesis of SWNTs using cost-effective early transition metals, illuminating their future applications in fields such as bioimaging.

01 Jul 2025·Separation and Purification Technology

Facile and low-cost method for preparing multilayer ceramic membranes based on cordierite and abundant clay: Application to dye removal

Author: Tabit, Kamal ; Mansori, Mohammed ; Waqif, Mohamed ; Boutaleb, Mouhssine ; Saadi, Latifa

Textile dyes represent a growing source of environmental pollution worldwide, affecting aquatic ecosystems and, by extension, human health.This study aims to develop low-cost ceramic membranes for the treatment of water contaminated by these dyes, using natural and economical materials.The membranes were made from abundant clay with different mass percentages of magnesium hydroxide, used as a pore-forming agent and were sintered at 900°C and 1000°C.To enhance filtration performance, the membranes were coated with a chem., phys., and thermally stable layer of refractory cordierite phase.This was achieved using a sedimentation technique, which allowed precise control overthe thickness and ensured the formation of a thin, homogeneous layer.The microstructural evolution of the membranes was examined using XRF, XRD, SEM, and DTA-TGA techniques, while their properties were assessed through measurements of flux, permeability, porosity, d., and mech. strength.Filtration performance was evaluated using a methylene blue solutionThe results indicated that membranes sintered at 900°C effectively filtered 99% to 99.8% of dyes, achieving fluxes between 46.36 and 84 L/(h·m2), with mech. strengths ranging from 79 to 113 MPa.For membranes sintered at 1000°C with 5% magnesium hydroxide, filtration performance improved from 50% to 99% with the addition of a cordierite layer, resulting in fluxes between 61 and 77 L/(h·m2) and compressive strengths from 60 MPa to 136 MPa.Production costs for ceramic membranes are estimated at around 12 to 46 USD/m2, due to the use of low-cost materials and reduced sintering temperaturesThe incorporation of the cordierite layer enhances the membranes suitability for demanding environments.

News (Medical) associated with Magnesium Hydroxide

02 Jan 2024

·synapse.patsnap.com

Demystifying H2 receptor antagonists: A Comprehensive Guide and How to Keep Up with the Latest Developments

The H2 receptor, also known as the histamine H2 receptor, plays a crucial role in the human body. It is primarily found in the stomach lining and is responsible for regulating the production of gastric acid. Activation of the H2 receptor by histamine leads to an increase in acid secretion, which aids in the digestion of food. However, excessive acid production can lead to conditions like gastric ulcers and gastroesophageal reflux disease (GERD). Therefore, pharmaceutical companies have developed H2 receptor antagonists, commonly known as H2 blockers, to inhibit the receptor's activity and reduce acid secretion, providing relief from acid-related disorders. Looking forward, the future of H2 receptor antagonists appears promising. Recent studies suggest that H2 receptor antagonists show significant promise as radioprotective agents. They could potentially be used for providing partial protection against radiation injury. Furthermore, there is ongoing research into repurposing H2 receptor antagonists for other uses. The global H2-receptor antagonists market is anticipated to grow at a substantial CAGR in the upcoming years. These developments suggest that H2 receptor antagonists could play a significant role in the treatment of various diseases in the future. The analysis of the target H2 receptor reveals a competitive landscape with multiple companies focusing on the development of drugs for various indications related to gastrointestinal disorders. GSK Plc is leading in terms of the highest number of drugs in the approved stage. Small molecule drugs are the most common drug type, indicating intense competition. China, the United States, Japan, and South Korea are the countries/locations with the highest development progress. China, in particular, has made significant progress in the development of drugs for the target H2 receptor. The future development of the target H2 receptor is expected to continue with a focus on innovative small molecule drugs and biosimilars, particularly in the treatment of gastrointestinal disorders. How do they work?H2 receptor antagonists, also known as H2 blockers, are a class of drugs that inhibit the action of histamine on the H2 receptors in the stomach. Histamine is a chemical released by cells in the stomach lining and stimulates the production of stomach acid. By blocking the H2 receptors, H2 receptor antagonists reduce the production of stomach acid, thereby decreasing acid-related symptoms and promoting healing of certain gastrointestinal conditions. From a biomedical perspective, H2 receptor antagonists are commonly used in the treatment of conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and gastritis. These drugs help alleviate symptoms like heartburn, acid reflux, and stomach pain by reducing the amount of acid produced in the stomach. They are often prescribed as a first-line treatment for these conditions and are available both over-the-counter and by prescription. Examples of H2 receptor antagonists include famotidine, ranitidine, and cimetidine. These drugs work by binding to the H2 receptors on the surface of stomach cells, preventing histamine from binding and triggering acid production. By reducing gastric acid secretion, H2 receptor antagonists provide relief from acid-related symptoms and promote the healing of damaged stomach lining. It's important to note that while H2 receptor antagonists are effective in managing certain gastrointestinal conditions, they may not be suitable for everyone. Individuals with certain medical conditions or taking specific medications should consult with their healthcare provider before using H2 receptor antagonists. Additionally, prolonged use of these drugs may have some side effects, such as headaches, dizziness, and diarrhea. Therefore, it is essential to follow the recommended dosage and duration of treatment as advised by a healthcare professional. List of H2 receptor AntagonistsThe currently marketed H2 receptor antagonists include: Ranitidine Hydrochloride/Bismuth Potassium Citrate/SucralfateFamotidine/IbuprofenRanitidine Hydrochloride/Bismuth Potassium CitrateRoxatidine Acetate HydrochlorideFamotidine/magnesium dihydroxide/Calcium carbonateLafutidineRanitidine Bismuth CitrateNizatidineFamotidineRanitidine HydrochlorideFor more information, please click on the image below. What are H2 receptor antagonists used for?H2 receptor antagonists are commonly used in the treatment of conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and gastritis. For more information, please click on the image below to log in and search. How to obtain the latest development progress of H2 receptor antagonists?In the Synapse database, you can keep abreast of the latest research and development advances of H2 receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Magnesium Hydroxide

External Link

KEGG	Wiki	ATC	Drug Bank
D00731	-	-	DB09104

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Constipation	Japan	MG Pharma Co. Ltd.	08 Oct 1952
Duodenal Ulcer	Japan	MG Pharma Co. Ltd.	08 Oct 1952
Gastritis	Japan	MG Pharma Co. Ltd.	08 Oct 1952
Stomach Ulcer	Japan	MG Pharma Co. Ltd.	08 Oct 1952

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal Reflux	Phase 2	Poland	Norgine BV	01 Apr 2011
Gastritis	Phase 2	-	GSK Plc	-
Gastritis	Phase 2	-	Merck Sharp & Dohme Corp.	-
Gastritis	Phase 2	-	Santarus, Inc.	-
Heartburn	Phase 2	United Kingdom	-	-
Heartburn	Phase 2	Bulgaria	-	-
Heartburn	Phase 2	Czechia	-	-
Heartburn	Phase 2	Hungary	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASTRO2015	Not Applicable	Prostatic Cancer	-	Milk of Magnesia	yoertuamsc(aydxkcxpnw) = n= 13/4 sqvyaahvcc (casrvpafat ) View more	-	01 Nov 2015
				Milk of Magnesia (Simple dietary advice)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Magnesium Hydroxide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation